Rebekah Rittberg

Winnipeg, MB R3E0V9, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Corrigendum to "Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)" [Lung Cancer 210 (2025) 108840].

Corrigendum to "Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)" [Lung Cancer 210 (2025) 108840].

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 17, 2025

Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE).

Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 17, 2025

Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer Under-Represented by Clinical Trials.

Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer Under-Represented by Clinical Trials.

Journal: Current oncology (Toronto, Ont.)

Published: August 05, 2024

Treating anaplastic lymphoma kinase (ALK) fusion-driven metastatic non-small cell lung cancer (NSCLC) with alectinib through pregnancy.

Treating anaplastic lymphoma kinase (ALK) fusion-driven metastatic non-small cell lung cancer (NSCLC) with alectinib through pregnancy.

Journal: BMJ case reports

Published: March 26, 2024

Impact of age, comorbidity, and polypharmacy on receipt of systemic therapy in advanced cancers: A retrospective population-based study.

Impact of age, comorbidity, and polypharmacy on receipt of systemic therapy in advanced cancers: A retrospective population-based study.

Journal: Journal of geriatric oncology

Published: July 08, 2023

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy.

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy.

Journal: Current oncology (Toronto, Ont.)

Published: April 02, 2023

Real-world predictors of survival in patients with extensive-stage small-cell lung cancer in Manitoba, Canada: a retrospective cohort study.

Real-world predictors of survival in patients with extensive-stage small-cell lung cancer in Manitoba, Canada: a retrospective cohort study.

Journal: Frontiers in oncology

Published: March 22, 2023

Real-world predictors of survival in patients with limited-stage small-cell lung cancer in Manitoba, Canada.

Real-world predictors of survival in patients with limited-stage small-cell lung cancer in Manitoba, Canada.

Journal: Frontiers in oncology

Published: March 22, 2023

Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing.

Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing.

Journal: Current oncology (Toronto, Ont.)

Published: October 26, 2022

Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization.

Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization.

Journal: Current oncology (Toronto, Ont.)

Published: October 04, 2022

Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer.

Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer.

Journal: Frontiers in oncology

Published: July 25, 2022

Acute Onset of a Life-Threatening Skin Toxicity Due to Osimertinib: Severe Psoriasis Versus Toxic Epidermal Necrolysis.

Acute Onset of a Life-Threatening Skin Toxicity Due to Osimertinib: Severe Psoriasis Versus Toxic Epidermal Necrolysis.

Journal: Cureus

Published: April 24, 2022

Showing 1-12 of 26

Last Updated: 09/26/2026